Feedback
Androstenedione
2001638
Ordering Recommendation

Aids in the investigation of virilizing endocrinopathies and in managing congenital adrenal hyperplasia in conjunction with other sex steroids. Not recommended for initial evaluation of polycystic ovarian syndrome.

Mnemonic
ANDRO TMS
Methodology
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Specimen should be collected between 6-10 a.m.  
Collect
Serum separator tube or green (sodium or lithium heparin).  
Specimen Preparation
Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.3 mL) Also acceptable: EDTA plasma.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
 
Remarks
 
Stability
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months  
Reference Interval
Effective August 19, 2013
AgeFemaleMale
Premature Infants, 26-28 weeks-Day 40.92-2.82 ng/mL0.92-2.82 ng/mL
Premature Infants, 31-35 weeks-Day 40.80-4.46 ng/mL0.80-4.46 ng/mL
Full-term Infants, 1-7 days0.20-2.90 ng/mL0.20-2.90 ng/mL
8-30 days0.18-0.80 ng/mL0.18-0.80 ng/mL
1-5 months0.06-0.68 ng/mL0.06-0.68 ng/mL
6-24 monthsLess than 0.15 ng/mL0.03-0.15 ng/mL
2-3 yearsLess than 0.16 ng/mLLess than 0.11 ng/mL
4-5 years0.02-0.21 ng/mL0.02-0.17 ng/mL
6-7 years0.02-0.28 ng/mL0.01-0.29 ng/mL
8-9 years0.04-0.42 ng/mL0.03-0.30 ng/mL
10-11 years0.09-1.23 ng/mL0.07-0.39 ng/mL
12-13 years0.24-1.73 ng/mL0.10-0.64 ng/mL
14-15 years0.39-2.00 ng/mL0.18-0.94 ng/mL
16-17 years0.35-2.12 ng/mL0.30-1.13 ng/mL
18-39 years0.26-2.14 ng/mL0.33-1.34 ng/mL
40 years and older0.13-0.82 ng/mL0.23-0.89 ng/mL
Pre-menopausal0.26-2.14 ng/mLDoes Not Apply
Postmenopausal0.13-0.82 ng/mLDoes Not Apply
Tanner Stage I0.05-0.51 ng/mL0.04-0.32 ng/mL
Tanner Stage II0.15-1.37 ng/mL0.08-0.48 ng/mL
Tanner Stage III0.37-2.24 ng/mL0.14-0.87 ng/mL
Tanner Stage IV-V0.35-2.05 ng/mL0.27-1.07 ng/mL

Interpretive Data


Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
CPT Code(s)
82157
Components
Component Test Code*Component Chart NameLOINC
2001639Androstenedione by TMS1854-9
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases